The DOI matches its Crossref record; 67 of the 67 references it cites were found in a registry or an index.
The Pharmacology of PEGylation: Balancing PD with PK to Generate Novel Therapeutics
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Effect of pegylation on pharmaceuticals
Harris, J. M., & Chess, R. B. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1033 · Cited by 3,431
Chemistry for peptide and protein PEGylation
Roberts, M. J., Bentley, M. D., & Harris, J. M. (2002) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(02)00022-4 · Cited by 1,604
Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease
Ng, E. W. M., Shima, D. T., Calias, P., Cunningham, E. T., Guyer, D. R., & Adamis, A. P. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd1955 · Cited by 1,588
Abuchowski, A., McCoy, J. R., Palczuk, N. C., van Es, T., & Davis, F. F. (1977) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)40292-4 · Cited by 1,274
Peginterferon Alfa-2a in Patients with Chronic Hepatitis C
Zeuzem, S., Feinman, S. V., Rasenack, J., Heathcote, E. J., Lai, M.-Y., Gane, E., O'Grady, J., Reichen, J., Diago, M., Lin, A., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200012073432301 · Cited by 1,220
Melmed, S. (2006) · New England Journal of Medicine · doi:10.1056/nejmra062453 · Cited by 1,160
Mechanism of action of interferon and ribavirin in treatment of hepatitis C
Feld, J. J., & Hoofnagle, J. H. (2005) · Nature · doi:10.1038/nature04082 · Cited by 992
Treatment of Acromegaly with the Growth Hormone–Receptor Antagonist Pegvisomant
Trainer, P. J., Drake, W. M., Katznelson, L., Freda, P. U., Herman-Bonert, V., van der Lely, A. J., Dimaraki, E. V., Stewart, P. M., Friend, K. E., Vance, M. L., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200004203421604 · Cited by 879
Effective drug delivery by PEGylated drug conjugates
Greenwald, R. B., Choe, Y. H., McGuire, J., & Conover, C. D. (2003) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(02)00180-1 · Cited by 869
Yamaoka, T., Tabata, Y., & Ikada, Y. (1994) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.2600830432 · Cited by 748
Ruckman, J., Green, L. S., Beeson, J., Waugh, S., Gillette, W. L., Henninger, D. D., Claesson-Welsh, L., & Janjic, N. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.32.20556 · Cited by 744
Bailon, P., Palleroni, A., Schaffer, C. A., Spence, C. L., Fung, W.-J., Porter, J. E., Ehrlich, G. K., Pan, W., Xu, Z.-X., Modi, M. W., et al. (2001) · Bioconjugate Chemistry · doi:10.1021/bc000082g · Cited by 611
PEGylated antibodies and antibody fragments for improved therapy: a review
Chapman, A. P. (2002) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(02)00026-1 · Cited by 556
Aptamers as therapeutic and diagnostic agents
Brody, E. N., & Gold, L. (2000) · Reviews in Molecular Biotechnology · doi:10.1016/s1389-0352(99)00004-5 · Cited by 494
Peginterferon and Ribavirin for Chronic Hepatitis C
Hoofnagle, J. H., & Seeff, L. B. (2006) · New England Journal of Medicine · doi:10.1056/nejmct061675 · Cited by 476
Generalisability in economic evaluation studies in healthcare: a review and case studies
Sculpher, M., Pang, F., Manca, A., Drummond, M., Golder, S., Urdahl, H., Davies, L., & Eastwood, A. (2004) · Health Technology Assessment · doi:10.3310/hta8490 · Cited by 441
Beckman, J. S., Minor, R. L., White, C. W., Repine, J. E., Rosen, G. M., & Freeman, B. A. (1988) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)68727-7 · Cited by 417
Polyethylene glycol-conjugated superoxide dismutase and catalase reduce ischemic brain injury
Liu, T. H., Beckman, J. S., Freeman, B. A., Hogan, E. L., & Hsu, C. Y. (1989) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.1989.256.2.h589 · Cited by 362
Growth Hormone Receptor Antagonists: Discovery, Development, and Use in Patients with Acromegaly
Kopchick, J. J., Parkinson, C., Stevens, E. C., & Trainer, P. J. (2002) · Endocrine Reviews · doi:10.1210/er.2001-0022 · Cited by 352
Therapeutic antibody fragments with prolonged in vivo half-lives
Chapman, A. P., Antoniw, P., Spitali, M., West, S., Stephens, S., & King, D. J. (1999) · Nature Biotechnology · doi:10.1038/11717 · Cited by 350
PEGylated Proteins: Evaluation of Their Safety in the Absence of Definitive Metabolism Studies
Webster, R., Didier, E., Harris, P., Siegel, N., Stadler, J., Tilbury, L., & Smith, D. (2007) · Drug Metabolism and Disposition · doi:10.1124/dmd.106.012419 · Cited by 337
Pegaspargase: a review of clinical studies
Graham, M. (2003) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(03)00110-8 · Cited by 322
Ensor, M., Holtsberg, F. W., Bomalaski, J. S., & Clark, M. A. (2002) · PubMed · Cited by 315
The Design and Development of Pegfilgrastim (PEG-rmetHuG-CSF, Neulasta®)
Molineux, G. (2004) · Current Pharmaceutical Design · doi:10.2174/1381612043452613 · Cited by 283
The enzyme as drug: application of enzymes as pharmaceuticals
Vellard, M. (2003) · Current Opinion in Biotechnology · doi:10.1016/s0958-1669(03)00092-2 · Cited by 283
Veronese, F. M., Schiavon, O., Pasut, G., Mendichi, R., Andersson, L., Tsirk, A., Ford, J., Wu, G., Kneller, S., Davies, J., et al. (2005) · Bioconjugate Chemistry · doi:10.1021/bc040241m · Cited by 282
Polyethylene glycol–superoxide dismutase, a conjugate in search of exploitation
Veronese, F. M., Caliceti, P., Schiavon, O., & Sergi, M. (2002) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(02)00029-7 · Cited by 273
Long-acting Growth Hormones Produced by Conjugation with Polyethylene Glycol
Clark, R., Olson, K., Fuh, G., Marian, M., Mortensen, D., Teshima, G., Chang, S., Chu, H., Mukku, V., Canova-Davis, E., et al. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.36.21969 · Cited by 246
Molineux, G., Kinstler, O., Briddell, B., Hartley, C., McElroy, P., Kerzic, P., Sutherland, W., Stoney, G., Kern, B., Fletcher, F. A., et al. (1999) · Experimental Hematology · doi:10.1016/s0301-472x(99)00112-5 · Cited by 243
Effects of PEG conjugation on insulin properties
Hinds, K. D., & Kim, S. W. (2002) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(02)00025-x · Cited by 240
Novel Approach to Specific Growth Factor Inhibition in Vivo
Floege, J., Ostendorf, T., Janssen, U., Burg, M., Radeke, H. H., Vargeese, C., Gill, S. C., Green, L. S., & Janjic, N. (1999) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)65263-7 · Cited by 233
Sundy, J. S., Ganson, N. J., Kelly, S. J., Scarlett, E. L., Rehrig, C. D., Huang, W., & Hershfield, M. S. (2007) · Arthritis & Rheumatism · doi:10.1002/art.22403 · Cited by 221
Shepherd, J., Brodin, H., Cave, C., Waugh, N., Price, A., & Gabbay, J. (2004) · Health Technology Assessment · doi:10.3310/hta8390 · Cited by 211
Site-specific PEGylation of a lysine-deficient TNF-α with full bioactivity
Yamamoto, Y., Tsutsumi, Y., Yoshioka, Y., Nishibata, T., Kobayashi, K., Okamoto, T., Mukai, Y., Shimizu, T., Nakagawa, S., Nagata, S., et al. (2003) · Nature Biotechnology · doi:10.1038/nbt812 · Cited by 208
Drolet, D. W., Nelson, J., Tucker, C. E., Zack, P. M., Nixon, K., Bolin, R., Judkins, M. B., Farmer, J. A., Wolf, J. L., Gill, S. C., et al. (2000) · Pharmaceutical Research · doi:10.1023/a:1007657109012 · Cited by 206
Structural and Biologic Characterization of Pegylated Recombinant IFN- α 2b
Grace, M., Youngster, S., Gitlin, G., Sydor, W., Xie, L., Westreich, L., Jacobs, S., Brassard, D., Bausch, J., & Bordens, R. (2001) · Journal of Interferon & Cytokine Research · doi:10.1089/107999001317205240 · Cited by 173
PEG-ADA replacement therapy for adenosine deaminase deficiency: an update after 8.5 years
Hershfield, M. S. (1995) · Clinical Immunology and Immunopathology · doi:10.1016/s0090-1229(95)90306-2 · Cited by 167
Foser, S., Schacher, A., Weyer, K. A., Brugger, D., Dietel, E., Marti, S., & Schreitmüller, T. (2003) · Protein Expression and Purification · doi:10.1016/s1046-5928(03)00055-x · Cited by 165
Yamaoka, T., Tabata, Y., & Ikada, Y. (1995) · Journal of Pharmacy and Pharmacology · doi:10.1111/j.2042-7158.1995.tb05835.x · Cited by 157
Ross, R. J. M., Leung, K. C., Maamra, M., Bennett, W. F., Doyle, N. S., Waters, M. J., & Ho, K. K. Y. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.4.7403 · Cited by 154
Baker, D. P., Lin, E. Y.-S., Lin, K., Pellegrini, M., Petter, R. C., Chen, L. L., Arduini, R. M., Brickelmaier, M., Wen, D., Hess, D. M., et al. (2005) · Bioconjugate Chemistry · doi:10.1021/bc050237q · Cited by 144
Adenosine deaminase deficiency: clinical expression, molecular basis, and therapy.
Hershfield, M. S. (1998) · PubMed · Cited by 140
Rowinsky, E. K., Rizzo, J. D., Ochoa, L., Takimoto, C. H. M., Forouzesh, B., Schwartz, G. H., Hammond, L. A., Patnaik, A., Kwiatek, J., Goetz, A. D., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2003.03.143 · Cited by 132
Pepinsky, R. B., LePage, D., Gill, A., Chakraborty, A., Vaidyanathan, S., Green, M., Baker, D. P., Whalley, E. T., Hochman, P. S., & Martin, P. L. (2001) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)29633-6 · Cited by 127
Synthesis, Characterization, and Pharmacokinetic Studies of PEGylated Glucagon-like Peptide-1
Lee, S., Lee, S., Youn, Y. S., Na, D. H., Chae, S. Y., Byun, Y., & Lee, K. C. (2005) · Bioconjugate Chemistry · doi:10.1021/bc049735+ · Cited by 123
Pepinsky, R. B., LePage, D., Gill, A., Chakraborty, A., Vaidyanathan, S., Green, M., Baker, D. P., Whalley, E. T., Hochman, P. S., & Martin, P. L. (2001) · PubMed · Cited by 119
Clinical pharmacology of polyethylene glycol-L-asparaginase.
Ho, D. H., Brown, N. S., Yen, A., Holmes, R., Keating, M. J., Abuchowski, A., Newman, R. A., & Krakoff, I. H. (1986) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(25)08348-5 · Cited by 119
Bomalaski, J. S., Holtsberg, F. W., Ensor, M., & Clark, M. A. (2002) · PubMed · Cited by 98
Tanaka, H., Satake-Ishikawa, R., Ishikawa, M., Matsuki, S., & Asano, K. (1991) · PubMed · Cited by 90
A review of the latest clinical compounds to inhibit VEGF in pathological angiogenesis
Baka, S., Clamp, A. R., & Jayson, G. C. (2006) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.10.6.867 · Cited by 90
Growth Hormone Receptor Antagonists
Muller, A. F., Kopchick, J. J., Flyvbjerg, A., & van der Lely, A. J. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-022049 · Cited by 89
Ps, P., Abuchowski, A., & Ff, D. (1980) · PubMed · Cited by 83
Doherty, D. H., Rosendahl, M. S., Smith, D. J., Hughes, J. M., Chlipala, E. A., & Cox, G. N. (2005) · Bioconjugate Chemistry · doi:10.1021/bc050172r · Cited by 80
Kelly, S. J., Delnomdedieu, M., Oliverio, M. I., WILLIAMS, D. L., Saifer, M. G. P., Sherman, M. R., Coffman, T. M., Johnson, G. A., & Hershfield, M. S. (2001) · Journal of the American Society of Nephrology · doi:10.1681/asn.v1251001 · Cited by 78
Adenosine deaminase deficiency: molecular basis and recent developments
Hirschhorn, R. (1995) · Clinical Immunology and Immunopathology · doi:10.1016/s0090-1229(95)90288-0 · Cited by 70
Ortiz, A. A., Milardo, L. F., DeCarr, L. B., Buckholz, T. M., Mays, M. R., Claus, T. H., Livingston, J. N., Mahle, C. D., & Lumb, K. J. (2007) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.107.125211 · Cited by 69
Lee, S., Youn, Y. S., Lee, S.-H., Byun, Y., & Lee, K. C. (2006) · Diabetologia · doi:10.1007/s00125-006-0234-3 · Cited by 66
Andersson, L. I., Davies, J., Duncan, R., Ferruti, P., Ford, J., Kneller, S., Mendichi, R., Pasut, G., Schiavon, O., Summerford, C., et al. (2005) · Biomacromolecules · doi:10.1021/bm049381p · Cited by 52
CDP-870 (certolizumab) in rheumatoid arthritis
Kaushik, V., & Moots, R. (2005) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.5.4.601 · Cited by 51
Pegylated arginine deiminase lowers hepatitis C viral titers and inhibits nitric oxide synthesis
Izzo, F., Montella, M., Orlando, A. P., Nasti, G., Beneduce, G., Castello, G., Cremona, F., Ensor, M., Holtzberg, F. W., Bomalaski, J. S., et al. (2006) · Journal of Gastroenterology and Hepatology · doi:10.1111/j.1440-1746.2006.04463.x · Cited by 42
MacEwen, E. G., ROSENTHAL, R. C., Matus, R. E., Viau, A. T., & Abuchowski, A. (1987) · Cancer · Cited by 41
Transitional Vacuole Formation Following a Bolus Infusion of Peg-Hemoglobin in the Rat
Conover, C., Lejeune, L., Linberg, R., Shum, K. L., & Shorr, R. (1996) · Artificial Cells Blood Substitutes and Biotechnology · doi:10.3109/10731199609118885 · Cited by 37
Intranasal Delivery of PEGylated Salmon Calcitonins: Hypocalcemic Effects in Rats
Lee, K. C., Myung Ok, P. A. R. K., Na, D. H., Youn, Y. S., Lee, S. D., Yoo, S. D., Lee, H. S., & DeLuca, P. P. (2003) · Calcified Tissue International · doi:10.1007/s00223-002-0034-9 · Cited by 34
Immunogenicity of polyethylene glycol-modified superoxide dismutase and catalase
Nucci, M. L., Olejarczyk, J., & Abuchowski, A. (1986) · Journal of Free Radicals in Biology & Medicine · doi:10.1016/s0748-5514(86)80031-9 · Cited by 31
Holdaway, I. M. (2004) · Hormone Research in Paediatrics · doi:10.1159/000080505 · Cited by 30
Wang, M., Basu, A., Palm, T., Hua, J., Youngster, S. K., Hwang, L. A., Liu, H.-C., Li, X., Peng, P., Zhang, Y., et al. (2006) · Bioconjugate Chemistry · doi:10.1021/bc060198y · Cited by 27
Polyethylene glycol modification of interleukin-6 enhances its thrombopoietic activity
Tsutsumi, Y. M., Kihira, T., Tsunoda, S., Okada, N., Kaneda, Y., Ohsugi, Y., Miyake, M., Nakagawa, S., & Mayumi, T. (1995) · Journal of Controlled Release · doi:10.1016/0168-3659(94)00121-a · Cited by 22
Cited by
Designing hydrogels for controlled drug delivery
Li, J., & Mooney, D. J. (2016) · Nature Reviews Materials · doi:10.1038/natrevmats.2016.71 · Cited by 4,832
The Impact of PEGylation on Biological Therapies
Veronese, F. M., & Mero, A. (2008) · BioDrugs · doi:10.2165/00063030-200822050-00004 · Cited by 1,034
Dhar, S., Gu, F. X., Langer, R., Farokhzad, O. C., & Lippard, S. J. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0809154105 · Cited by 994
Yusuf, A., Almotairy, A. R. Z., Henidi, H., Alshehri, O. Y., & Aldughaim, M. S. (2023) · Polymers · doi:10.3390/polym15071596 · Cited by 914
Herzberger, J., Niederer, K., Pohlit, H., Seiwert, J., Worm, M., Wurm, F. R., & Frey, H. (2016) · Chemical Reviews · doi:10.1021/acs.chemrev.5b00441 · Cited by 865
Metadata
- Authors
- Fishburn, C. S.
- Venue
- Journal of Pharmaceutical Sciences
- Publisher
- Elsevier BV
- Published
- 2008-10
- Volume
- 97
- Issue
- 10
- Pages
- 4167-4183
- ISSN
- 0022-3549 (ISSN-L)
- OpenAlex
- W2124140010
- Cited by
- 474
- References
- 67
- FWCI
- 17.15
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.